Cargando…

ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma

We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expr...

Descripción completa

Detalles Bibliográficos
Autores principales: Krakstad, Camilla, Tangen, Ingvild L., Hoivik, Erling A., Halle, Mari K., Berg, Anna, Werner, Henrica M., Ræder, Maria B., Kusonmano, Kanthida, Zou, June X., Øyan, Anne M., Stefansson, Ingunn, Trovik, Jone, Kalland, Karl-Henning, Chen, Hong-Wu, Salvesen, Helga B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/
https://www.ncbi.nlm.nih.gov/pubmed/26308378
_version_ 1782407589354536960
author Krakstad, Camilla
Tangen, Ingvild L.
Hoivik, Erling A.
Halle, Mari K.
Berg, Anna
Werner, Henrica M.
Ræder, Maria B.
Kusonmano, Kanthida
Zou, June X.
Øyan, Anne M.
Stefansson, Ingunn
Trovik, Jone
Kalland, Karl-Henning
Chen, Hong-Wu
Salvesen, Helga B.
author_facet Krakstad, Camilla
Tangen, Ingvild L.
Hoivik, Erling A.
Halle, Mari K.
Berg, Anna
Werner, Henrica M.
Ræder, Maria B.
Kusonmano, Kanthida
Zou, June X.
Øyan, Anne M.
Stefansson, Ingunn
Trovik, Jone
Kalland, Karl-Henning
Chen, Hong-Wu
Salvesen, Helga B.
author_sort Krakstad, Camilla
collection PubMed
description We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor α (ERα) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated (P < 0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials.
format Online
Article
Text
id pubmed-4695070
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Impact Journals LLC
record_format MEDLINE/PubMed
spelling pubmed-46950702016-01-20 ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma Krakstad, Camilla Tangen, Ingvild L. Hoivik, Erling A. Halle, Mari K. Berg, Anna Werner, Henrica M. Ræder, Maria B. Kusonmano, Kanthida Zou, June X. Øyan, Anne M. Stefansson, Ingunn Trovik, Jone Kalland, Karl-Henning Chen, Hong-Wu Salvesen, Helga B. Oncotarget Research Paper We have explored the potential for clinical implementation of ATAD2 as a biomarker for aggressive endometrial cancer by investigating to what extent immunohistochemical (IHC) staining for ATAD2 is feasible, reflects clinical phenotype and molecular subgroups of endometrial carcinomas. Increased expression of the ATAD2 gene has been implicated in cancer development and progression in a number of tissues, but few studies have investigated ATAD2 expression using IHC. Here we show that high ATAD2 protein expression is significantly associated with established clinical-pathological variables for aggressive endometrial cancer, also in the subset of estrogen receptor α (ERα) positive tumors. Protein and mRNA expression of ATAD2 were highly correlated (P < 0.001), suggesting that IHC staining may represent a more clinically applicable measure of ATAD2 level in routinely collected formalin fixed paraffin embedded specimens. Gene expression alterations in samples with high ATAD2 expression revealed upregulation of several cancer-related genes (B-MYB, CDCs, E2Fs) and gene sets that previously have been linked to aggressive disease and potential for new targeting therapies. Our results support that IHC staining for ATAD2 may be a clinically applicable biomarker reflecting clinical phenotype and targetable alterations in endometrial carcinomas to be further explored in controlled clinical trials. Impact Journals LLC 2015-07-22 /pmc/articles/PMC4695070/ /pubmed/26308378 Text en Copyright: © 2015 Krakstad et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Paper
Krakstad, Camilla
Tangen, Ingvild L.
Hoivik, Erling A.
Halle, Mari K.
Berg, Anna
Werner, Henrica M.
Ræder, Maria B.
Kusonmano, Kanthida
Zou, June X.
Øyan, Anne M.
Stefansson, Ingunn
Trovik, Jone
Kalland, Karl-Henning
Chen, Hong-Wu
Salvesen, Helga B.
ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
title ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
title_full ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
title_fullStr ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
title_full_unstemmed ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
title_short ATAD2 overexpression links to enrichment of B-MYB-translational signatures and development of aggressive endometrial carcinoma
title_sort atad2 overexpression links to enrichment of b-myb-translational signatures and development of aggressive endometrial carcinoma
topic Research Paper
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4695070/
https://www.ncbi.nlm.nih.gov/pubmed/26308378
work_keys_str_mv AT krakstadcamilla atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT tangeningvildl atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT hoivikerlinga atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT hallemarik atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT berganna atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT wernerhenricam atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT rædermariab atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT kusonmanokanthida atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT zoujunex atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT øyanannem atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT stefanssoningunn atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT trovikjone atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT kallandkarlhenning atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT chenhongwu atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma
AT salvesenhelgab atad2overexpressionlinkstoenrichmentofbmybtranslationalsignaturesanddevelopmentofaggressiveendometrialcarcinoma